New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:22 EDTEGLT, CORT, EBS, RPTP, OVAS, DRTXJanney Capital to hold a conference
2nd Annual Healthcare 1x1 Corporate Access Day to be held in Boston on June 26.
News For RPTP;CORT;DRTX;EBS;EGLT;OVAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
12:25 EDTCORTCorcept Therapeutics Chief Accounting Officer retires
Subscribe for More Information
July 6, 2015
09:15 EDTRPTPOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTRPTPRaptor downgraded to Underperform from Perform at Oppenheimer
Oppenheimer analyst Chris Marai downgraded Raptor Pharmaceuticals to Underperform with an $8 price target. A takeout of the company is unlikely at current valuation levels, Marai tells investors in a research note. He recommends selling the stock.
July 2, 2015
16:52 EDTEGLTEgalet files to sell $30M of common stock
Subscribe for More Information
09:23 EDTCORTCorcept Therapeutics management to meet with FBR Capital
Subscribe for More Information
07:53 EDTEGLTEgalet data misunderstood, weakness unwarranted, says Canaccord
Subscribe for More Information
June 30, 2015
06:05 EDTEGLTEgalet announces top-line results from Category 3 HAL study of Egalet-002
Egalet announced top-line results from a Category 3 human abuse liability, or HAL, study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The study was a randomized, double-blind, active and placebo-controlled, five-way crossover study which compared the abuse potential of manipulated and intact Egalet-002 versus manipulated IR oxycodone following oral administration in 47 nondependent recreational opioid users. In addition, an exploratory sixth arm was added which compared the abuse potential of Egalet-002 to the currently marketed abuse-deterrent formulation of OxyContin, which does not have an oral abuse-deterrent claim in its label, in 28 nondependent recreational opioid users. The study was conducted with the development formulation of Egalet-002, to inform our clinical development efforts for a pivotal oral HAL study with 'to be marketed' product, consistent with the FDA Guidance.
June 29, 2015
10:09 EDTOVASOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTOVASOvaScience initiated with a Neutral at JPMorgan
Subscribe for More Information
06:09 EDTEGLTEgalet announces positive top-line results from Egalet-001 study
Egalet announced positive results from a Category 3 intranasal human abuse liability, or HAL, study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The clinical HAL study demonstrated that, in nondependent, recreational opioid users, the abuse potential of manipulated Egalet-001 taken intranasally was significantly lower than that for manipulated MS Contin. Bob Radie, president and CEO at Egalet, stated, "With this strong intranasal HAL data combined with the previously announced positive oral HAL data, and the category 1 studies, Egalet-001 continues to demonstrate a very promising abuse-deterrent profile. With this data, we have successfully completed the clinical studies necessary to file our NDA for Egalet-001, which we plan to submit in Q4."
June 25, 2015
06:10 EDTEGLTEgalet Egalet-001 demonstrates bioequivalence at 60 mg dose
Egalet announced top-line results from a pivotal pharmacokinetic study demonstrating bioequivalence of Egalet-001 60 mg to MS Contin 60 mg. Egalet-001 is an abuse-deterrent, extended-release, oral morphine product in late-stage development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. In addition to this 60 mg bioequivalence study, Egalet announced in March top-line results from another pharmacokinetic study which demonstrated bioequivalence of Egalet-001 15 mg and 30 mg to comparable doses of MS Contin.
June 23, 2015
07:36 EDTOVASJMP Securities to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use